Share

October 2013; 3 (5) Drugs and Devices

Intravenous immunoglobulin for treatment of neuromuscular disease

Katherine Ruzhansky, Thomas H. Brannagan
First published October 4, 2013, DOI: https://doi.org/10.1212/CPJ.0b013e3182a78ecf
Full PDF
Citation
Permissions

Make Comment

See Comments

Downloads
356

Share

Article Information

vol. 3 no. 5 440-445
DOI: 
https://doi.org/10.1212/CPJ.0b013e3182a78ecf
Published By: 
Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology
Print ISSN: 
2163-0402
Online ISSN: 
2163-0933
History: 
  • First Published October 4, 2013.

Article Versions

Copyright & Usage: 
© 2013 American Academy of Neurology

Author Disclosures

    1. Katherine Ruzhansky, MD and
    2. Thomas H. Brannagan III, MD
  1. Katherine Ruzhansky, MD and
    2. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. NONE

    Speakers' Bureaus:

    1. NONE

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  2. Thomas H. Brannagan III, MD
    3. Scientific Advisory Boards:

    1. NONE

    Gifts:

    1. NONE

    Funding for Travel or Speaker Honoraria:

    1. NONE

    Editorial Boards:

    1. NONE

    Patents:

    1. NONE

    Publishing Royalties:

    1. NONE

    Employment, Commercial Entity:

    1. NONE

    Consultancies:

    1. Grifols, Pfizer, CSL, Baxter

    Speakers' Bureaus:

    1. Grifols

    Other Activities:

    1. NONE

    Clinical Procedures or Imaging Studies:

    1. NONE

    Research Support, Commercial Entities:

    1. NONE

    Research Support, Government Entities:

    1. NONE

    Research Support, Academic Entities:

    1. NONE

    Research Support, Foundations and Societies:

    1. NONE

    Stock/Stock Options/Board of Directors Compensation:

    1. NONE

    License Fee Payments, Technology or Inventions:

    1. NONE

    Royalty Payments, Technology or Inventions:

    1. NONE

    Stock/Stock Options, Research Sponsor:

    1. NONE

    Stock/Stock Options, Medical Equipment & Materials:

    1. NONE

    Legal Proceedings:

    1. NONE

  1. Peripheral Neuropathy Center, Neurological Institute, Columbia University, College of Physicians and Surgeons, New York, NY.
  1. Correspondence to:
    Tb2325{at}columbia.edu
View Full Text

Article usage

Article usage: October 2013 to July 2022

AbstractFullPdfSource
Oct 201390837107Highwire
Nov 20137112246Highwire
Dec 2013334415Highwire
Jan 201412125Highwire
Feb 20149812Highwire
Mar 20147603Highwire
Apr 20148904Highwire
May 20146425Highwire
Jun 20144301Highwire
Jul 20143121Highwire
Aug 20145201Highwire
Sep 20143921Highwire
Oct 20142703Highwire
Nov 20145916Highwire
Dec 20143801Highwire
Jan 20153100Highwire
Feb 20151710Highwire
Mar 20156405Highwire
Apr 20152600Highwire
May 20154002Highwire
Jun 20151402Highwire
Jul 20151802Highwire
Aug 20151104Highwire
Sep 20152413Highwire
Oct 20154603Highwire
Nov 20151811Highwire
Dec 20152300Highwire
Jan 20162501Highwire
Feb 20162600Highwire
Mar 20163821Highwire
Apr 20164301Highwire
May 20164101Highwire
Jun 20161500Highwire
Jul 20162326Highwire
Aug 20166601Highwire
Sep 20161900Highwire
Oct 20163010Highwire
Nov 20163100Highwire
Dec 20162000Highwire
Jan 20176301Highwire
Feb 20171702Highwire
Mar 20172200Highwire
Apr 20172200Highwire
May 20172501Highwire
Jun 20171800Highwire
Jul 20171100Highwire
Aug 20171600Highwire
Sep 20171000Highwire
Oct 20172000Highwire
Nov 20171300Highwire
Dec 2017901Highwire
Jan 2018800Highwire
Feb 20181920Highwire
Mar 20181711Highwire
Apr 20183510Highwire
Apr 2018153439pmc
May 20182211Highwire
Jun 20182510Highwire
Jun 201851411pmc
Jul 20181800Highwire
Aug 2018800Highwire
Aug 201873133pmc
Sep 2018814Highwire
Oct 2018933Highwire
Nov 20181801Highwire
Dec 20182110Highwire
Jan 20192110Highwire
Feb 20191914Highwire
Mar 20191410Highwire
Apr 20191211Highwire
May 2019900Highwire
Jun 20191000Highwire
Jul 2019700Highwire
Aug 2019200Highwire
Sep 20191544Highwire
Oct 20192210Highwire
Nov 20191801Highwire
Dec 20191501Highwire
Jan 20201200Highwire
Feb 20202000Highwire
Mar 20201100Highwire
Apr 2020611Highwire
May 20201400Highwire
Jun 2020711Highwire
Jul 2020701Highwire
Aug 20202200Highwire
Sep 20201200Highwire
Oct 20201000Highwire
Nov 20201200Highwire
Dec 20202100Highwire
Jan 2021600Highwire
Feb 2021900Highwire
Mar 20211700Highwire
Apr 20211200Highwire
May 20211100Highwire
Jun 2021910Highwire
Jul 20213801Highwire
Aug 20212611Highwire
Sep 20211500Highwire
Oct 20213313Highwire
Nov 20211942Highwire
Dec 20213122Highwire
Jan 20222310Highwire
Feb 20222000Highwire
Mar 20221710Highwire
Apr 20221500Highwire
May 20221100Highwire
Jun 20222610Highwire
Jul 20221501Highwire

The Nerve!: Rapid online correspondence

No comments have been published for this article.
Comment

REQUIREMENTS

If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org

Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.

If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.

Submission specifications:

  • Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
  • Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
  • Submit only on articles published within 6 months of issue date.
  • Do not be redundant. Read any comments already posted on the article prior to submission.
  • Submitted comments are subject to editing and editor review prior to posting.

More guidelines and information on Disputes & Debates

Compose Comment

More information about text formats

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.
Author Information
NOTE: The first author must also be the corresponding author of the comment.
First or given name, e.g. 'Peter'.
Your last, or family, name, e.g. 'MacMoody'.
Your email address, e.g. higgs-boson@gmail.com
Your role and/or occupation, e.g. 'Orthopedic Surgeon'.
Your organization or institution (if applicable), e.g. 'Royal Free Hospital'.
Publishing Agreement
NOTE: All authors, besides the first/corresponding author, must complete a separate Publishing Agreement Form and provide via email to the editorial office before comments can be posted.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.

Vertical Tabs

You May Also be Interested in

Back to top
Advertisement

Related Articles

  • No related articles found.

Topics Discussed

Alert Me